Results 91 to 100 of about 81,803 (228)
Untersuchungen zur Regulierung und Funktion der Mitogen-aktivierten Proteinkinase ERK5 = Regulation and Function of the Mitogen-activated Protein Kinase ERK5 [PDF]
, 2003 Mitogen activated protein kinases (MAPKs) are found in all eukaryotic cells and represent crucial elements in the signal transduction from the plasma membrane to the nucleus.
Buschbeck, Marcus
core
DETECTION OF BCR-ABL PROTEIN IN CHRONIC MYELOID LEUKEMIA PATIENTS USING IMMUNOCYTOCHEMISTRY
The Iraqi Journal of Medical Sciences, 2016 Background: Chronic Myeloid leukemia (CML) is a myeloproliferetive disorder associated with chromosomal abnormality, Philadelphia chromosome (Ph), in more than 95% of CML patients. The resulting BCR-ABL fused gene is markers for this type of leukemia. In
Maysaa Abdul Razaq Dhahi +2 more
doaj +6 more sources
Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
The Journal of biological chemistry, 1998 A 62-kDa Ras GTPase-activating protein (RasGAP)-associated protein is tyrosine-phosphorylated under a variety of circumstances including growth factor stimulation and in cells transformed by activated tyrosine kinases. A cDNA for p62(dok), reported to be the RasGAP-associated 62-kDa protein, was recently cloned from Abl-transformed cells. In this study,
A, Bhat +4 more
openaire +2 more sources
Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot +6 more
wiley +1 more source
Quantitative Assessment of the BCR-ABL Transcript Using the Cepheid Xpert BCR-ABL Monitor Assay
Archives of Pathology & Laboratory Medicine, 2007 Abstract Context. —Chronic myelogenous leukemia (CML) and the assessment of the BCR-ABL transcript has become a new paradigm. Novel tyrosine kinase inhibitors as mainstream therapeutic options for the CML patient warrant routine quantification of the
Scott D, Dufresne +3 more
openaire +2 more sources
Cancer Medicine, Volume 15, Issue 9, September 2026.ABSTRACT Background While overall survival for chronic myeloid leukemia (CML) at 5 years now exceeds 90% with modern tyrosine kinase inhibitor (TKI) therapies, disparities in management and outcomes persist among underserved populations. This study describes TKI treatment patterns and outcomes in a predominantly Hispanic, underserved CML cohort treated
Dominick Zheng +4 more
wiley +1 more source
Blood, 2008 Several RNA binding proteins (RBPs) have been implicated in the progression of chronic myelogenous leukemia (CML) from the indolent chronic phase to the aggressively fatal blast crisis. In the latter phase, expression and function of specific RBPs are aberrantly regulated at transcriptional or posttranslational levels by the constitutive kinase ...
Eiring AM +12 more
openaire +5 more sources
Cancer Medicine, Volume 15, Issue 9, September 2026.ABSTRACT Central nervous system (CNS) involvement in B‐cell acute lymphoblastic leukemia (B‐ALL) is associated with relapse, treatment refractoriness, and poor prognosis. Although chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (R/R) B‐ALL, its efficacy and safety in CNS leukemia (CNSL) remain ...
Yanghong Yu +3 more
wiley +1 more source
Elucidating the role of the tumor suppressor Protein Phoshatase 2A in Chronic Myeloid Leukemia. [PDF]
, 2010 Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine phosphatases and is involved in the regulation of cell homeostasis through the negative regulation of signaling pathways initiated by protein kinases.
Neviani, Paolo
core